Outbreaks of iatrogenic botulism in Europe: Combating off-label medical use of Botulinum Neurotoxin (BoNT) in bariatric procedures

Jain, Nityanand; Lansiaux, Edouard; Yucel, Umut; Huenermund, Swantje; Goeschl, Stella; Schlagenhauf, Patricia

doi:10.1016/j.nmni.2023.101152

Cited by 4 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 11 According to the report recently published by the World Health Organization, iatrogenic botulism cases have been reported in some countries, including our country. 28 The ideal dose and method of administration of intragastric BTX-A injection in the treatment of obesity have not been defined due to conflicting study results. For this reason, we see very different application doses and applications made by people who do not have sufficient competence.…”

Section: Discussionmentioning

confidence: 99%

Intragastric injection of botulinum toxin in the treatment of obesity: a single-center study

Köseoğlu,

Kenarli,

Akbay

et al. 2024

Clin Med Insights Gastroenterol

View full text Add to dashboard Cite

Background: In recent years, various novel surgical and non-surgical therapeutic options have been developed for treating obesity. Due to its disputed success, intragastric botulinum toxin A (BTX-A) injection is still being debated. Objectives: We aim to contribute to this controversial issue in the literature by sharing our center’s findings regarding intragastric BTX-A injections in the treatment of obesity. Design: Patients with a body mass index (BMI) of greater than 25 kg/m2 and at least one obesity-related complication, or a BMI of greater than 30 kg/m2 without complications, were eligible for the study if they were between the ages of 18 and 65. Methods: Following the same procedure, two endoscopists administered BTX-A to all patients. All patients were evaluated for obesity by measuring their lipid profile, hormone profile, and insulin resistance level before treatment. Results: In our study on 82 patients, we saw a significant mean weight loss (−9.2 kg, p < 0.001) in the second month, and there was no additional mean weight loss in the sixth month of follow-up. In addition, this result seems to be independent of the patient’s insulin resistance. We did not see any serious side effects in any of the patients. Conclusion: Although the use of intragastric injection of BTX-A in the treatment of obesity is a controversial issue, we showed in our study that it causes significant weight loss. Further studies are needed on this subject, as it can be a safe method when the ideal dose and application site are combined with appropriate patient selection.

show abstract

Section: Discussionmentioning

confidence: 99%

Intragastric injection of botulinum toxin in the treatment of obesity: a single-center study

Köseoğlu,

Kenarli,

Akbay

et al. 2024

Clin Med Insights Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Nevertheless, safety studies are required to guarantee safe dosing. Indeed, last year, a botulism outbreak occurred in Turkey following the injection of excessive BoNT doses in the stomach of patients [ 126 ]. Nevertheless, the potential benefit of BoNT is very promising because of the increasing incidence of cancer.…”

Section: An Expanding Range Of Indicationsmentioning

confidence: 99%

Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications

Rasetti-Escargueil,

Palea

2024

Toxins

View full text Add to dashboard Cite

Botulinum neurotoxins (BoNTs) have been used for almost half a century in the treatment of excessive muscle contractility. BoNTs are routinely used to treat movement disorders such as cervical dystonia, spastic conditions, blepharospasm, and hyperhidrosis, as well as for cosmetic purposes. In addition to the conventional indications, the use of BoNTs to reduce pain has gained increased recognition, giving rise to an increasing number of indications in disorders associated with chronic pain. Furthermore, BoNT-derived formulations are benefiting a much wider range of patients suffering from overactive bladder, erectile dysfunction, arthropathy, neuropathic pain, and cancer. BoNTs are categorised into seven toxinotypes, two of which are in clinical use, and each toxinotype is divided into multiple subtypes. With the development of bioinformatic tools, new BoNT-like toxins have been identified in non-Clostridial organisms. In addition to the expanding indications of existing formulations, the rich variety of toxinotypes or subtypes in the wild-type BoNTs associated with new BoNT-like toxins expand the BoNT superfamily, forming the basis on which to develop new BoNT-based therapeutics as well as research tools. An overview of the diversity of the BoNT family along with their conventional therapeutic uses is presented in this review followed by the engineering and formulation opportunities opening avenues in therapy.

show abstract

Drugs in focus: Botulinum toxin in the therapy of gastrointestinal disorders in children

Homan,

Thomson,

Bontems

et al. 2024

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

What is Known Botulinum toxin (BoNT) causes muscle relaxation by inhibiting acetylcholine release from presynaptic motor neurons at the neuromuscular junction.What is New In children with achalasia, BoNT can be considered only in patients in whom rapid weight gain is important to improve surgical outcomes. BoNT has been suggested for treating cricopharyngeal achalasia and delayed gastric emptying. Anal achalasia and constipation after Hirschsprung disease corrective surgery are very promising indications for BoNT use. In selected children with resistant type of functional constipation and chronic anal fissure, BoNT is a viable option for treating.

show abstract

Outbreaks of iatrogenic botulism in Europe: Combating off-label medical use of Botulinum Neurotoxin (BoNT) in bariatric procedures

Cited by 4 publications

References 20 publications

Intragastric injection of botulinum toxin in the treatment of obesity: a single-center study

Intragastric injection of botulinum toxin in the treatment of obesity: a single-center study

Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications

Drugs in focus: Botulinum toxin in the therapy of gastrointestinal disorders in children

Contact Info

Product

Resources

About